Improved quality of life (QoL) among seasonal allergic rhinitis (SAR) patients treated with olopatadine HCl nasal spray, 0.4% and olopatadine HCl nasal spray, 0.6% compared to vehicle*1

Rationale Since SAR causes a considerable impact on QoL, the Rhinoconjunctivitis Quality of Life (RQLQ) Questionnaire was used to assess the QoL impact of olopatadine HCl nasal spray compared to the vehicle. Methods The 28-item RQLQ, consisting of 7 domains (activities, sleep, non-hayfever symptoms, practical problems, nasal symptoms, eye symptoms, and emotional), was used to collect QoL data during a multicenter, randomized, double-masked SAR (mountain cedar) trial comparing olopatadine HCl nasal spray, 0.6% and 0.4% against the olopatadine vehicle. Patients, recruited with at least a 2-yr history of non-recalcitrant SAR, filled out the questionnaire at baseline (randomization visit), and again after 2 weeks at the exit (end of treatment) visit. Results Olopatadine 0.6% (−1.1 + −1.4) and 0.4% (−1.1 + −1.3) nasal sprays were superior (p Conclusions Both olopatadine HCl nasal sprays are superior to vehicle in improving overall QoL. While patients receiving olopatadine HCl nasal spray, 0.6% had significantly demonstrable improvement in all areas of their life except non-hayfever symptoms, patients receiving olopatadine 0.4% nasal spray had significant improvement in 5 out of the 7 total QoL areas.